You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
UK-based ATDBio will develop new oligonucleotide-tagged microbeads for use in droplet-based single-cell RNA sequencing, to be evaluated by researchers at Oxford.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.
The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.
Using 26 pediatric ependymoma patient samples, researchers sequenced 18,500 single cells to classify and analyze discrete neoplastic subpopulations.
Researchers have developed a method, called MemorySeq, to identify genes transcriptome-wide whose expression fluctuations persist for several cell divisions.
Codefendant 1Cellbio, an instrument maker that had obtained a co-exclusive license to the patents, said it plans to appeal the court's declaration.
A team of researchers in Germany investigated gene expression in airway cells of SARS-CoV-2 patients, finding increased interaction between epithelial and immune cells.
The SICILIAN algorithm, which uses statistical modeling to score candidate fusions in single-cell RNA sequencing data, is being used to map splice sites in individual tumor cells.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.